La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Mereo BioPharma Group a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Mereo BioPharma Group..

Mereo BioPharma Group (NASDAQ:MREO) Azioni, Catena delle Opzioni

Mereo BioPharma Group

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group PLC

Mereo BioPharma: Positioned For Potential Breakthroughs

HRTS: Generating Alpha In Obesity Treatment

Mereo BioPharma Group GAAP EPS of -$0.02

Analyst Gil Blum of Needham maintained a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report), retaining the price target of $7.00. Gil...

Mereo Biopharma Group: A Strong Buy on Promising Clinical Data and Robust Financials

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on MREO stock, giving a Buy rating on August 13. Joseph Schwartz has g...

Strong Buy Rating for Mereo Biopharma Amidst Promising Drug Program Developments

New additions to Roth MKM's ADR portfolio for September

Mereo BioPharma - Lazarus-Like Recovery Impresses, But Lack Of Clarity On Potential Approval Timelines

"The Phase 3 program for setrusumab, led by our partners at Ultragenyx, continues to progress according to plan and we look forward to reporting th...

Mereo BioPharma reports Q3 EPS (2c), consensus (2c)

Analyst Gil Blum from Needham maintained a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report) and keeping the price target at $7.00. ...

Mereo Biopharma Group: Anticipated Positive Developments and Strong Financial Position Justify Buy Rating

Mereo Biopharma ( ($MREO) ) has released its Q3 earnings. Here is a breakdown of the information Mereo Biopharma presented to its investors. Mereo ...

Mereo BioPharma: Strong Cash Position Amid Clinical Progress

AMGN

ARGT

ARGX

ATAT

BGNE

BWAY

CNTA

CRESY

CYTK

GGAL

HRTS

LOMA

MOMO

MREO

QFIN

RARE

SONY

VNET

VRNA

Earnings

Press Releases

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

News

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

Financing

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Abivax

Altimmune

AnaptysBio

Annexon

Astria Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

GRAIL

Humacyte

IGM Biosciences

Immunome

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Organogenesis Hldgs

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

PureTech Health plc - American Depositary Shares

PureTech Health

Sana Biotechnology

Stoke Therapeutics

Savara

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Tourmaline Bio

Needham

Cantor Fitzgerald

Leerink Partners

Baird

SVB Leerink

Comments

Mereo BioPharma Group

Mereo BioPharma Group (MREO) Opzioni

Mereo BioPharma Group (NASDAQ:MREO) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO